Testing a prostate-sparing bladder surgery for bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies whether a “prostate-sparing” radical cystectomy is safe and effective for bladder cancer patients who are having surgery. It aims to see if this approach can treat bladder cancer while reducing prostate-related side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (over 18 years old).
- You have confirmed bladder cancer and are planning radical cystectomy surgery.
- You can read and understand the study and agree to sign written consent.
- You should be a candidate for bladder removal surgery (not someone who can’t have cystectomy).
- Your erections should not be moderately to severely affected (SHIM score must be 17 or higher).
- You should not have prostate involvement in the bladder area (like cancer involving the bladder neck/prostatic urethra).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a redesigned surgical instrument used during bladder tumor removal, to see if it can improve how the removed tissue samples are collected. It may help future patients by supporting better study of bladder tissue during cancer care.
This trial compares two types of bladder surgery to see which works better for certain men with bladder cancer. It may help you and your doctors choose the safest option that controls the cancer while preserving quality of life.
This trial tests whether using a patient's own tumor cells in lab-made clusters (PTCs) can help guide chemotherapy before bladder removal surgery for muscle-invasive bladder cancer. If you qualify, you'll receive personalized treatment followed by surgery.
This study looks at whether removing nearby lymph nodes during radical cystectomy (bladder removal) improves outcomes for people with high-risk non–muscle-invasive bladder cancer. It may help doctors choose the best surgical approach to reduce the chance of cancer coming back.
This trial tests a combination of chemotherapy and immunotherapy to treat large, non-invasive bladder cancer before and after surgery. It aims to avoid removing the bladder while still effectively treating the cancer.
This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (etoposide and cisplatin) given before surgery for a rare, aggressive type of bladder cancer called neuroendocrine carcinoma. The goal is to see if this approach can shrink the tumor and improve outcomes.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.